Abstract

252P Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract P2-02-12: Computer derived image features on DCE-MRI appear to distinguish estrogen receptor-positive breast cancers with low and high oncotype DX recurrence scores
N Avril ... C Thompson
Cancer Research | VOL. 73
N Avril, et. al.N Avril ... C Thompson
15 Dec 2013
Abstract P3-01-06: Correlation of disseminated or circulating tumor cells with the OncotypeDX recurrence score
S Meas ... Se Tevis
Cancer Research | VOL. 79
S Meas, et. al.S Meas ... Se Tevis
15 Feb 2019
Abstract P2-11-12: Validation of modified Magee equations for predicting the oncotype DX recurrence score: A cost-effective alternative for estimating the risk of distant recurrence in receptor positive/node negative breast cancer patients
D Hicks ... P Tang
Cancer Research | VOL. 73
D Hicks, et. al.D Hicks ... P Tang
15 Dec 2013
Can Features Evaluated in the Routine Pathologic Assessment of Lymph Node–Negative Estrogen Receptor–Positive Stage I or II Invasive Breast Cancer Be Used to Predict the Oncotype DX Recurrence Score?
Jena Auerbach ... Mimi Kim
Archives of Pathology & Laboratory Medicine | VOL. 134
Jena Auerbach, et. al.Jena Auerbach ... Mimi Kim
01 Nov 2010
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: “ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe”, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
H Li ... E Song
Annals of Oncology | VOL. -
H Li, et. al.H Li ... E Song
01 May 2024
View more papers